GE HealthCare Technologies Inc. (GEHC) is scheduled to report first-quarter 2025 results on April 30, before market open.In the last reported quarter, the company’s adjusted earnings per share of $1.45 beat the Zacks Consensus Estimate by 15.1%.Stay up-to-date with all quarterly releases: See Zacks Earnings Calendar.Let us look at how things have shaped up for GEHC prior to the announcement.Factors That Might Have Driven GEHC’s Q1 PerformanceGE HealthCare is poised to benefit from ongoing robust procedure v ...

According to the collective judgment of analysts, 'Revenues- Imaging' should come in at $2.03 billion. The estimate indicates a year-over-year change of -17.8%. Based on the collective assessment of analysts, 'Revenues- Ultrasound' should arrive at $1.22 billion. The estimate suggests a change of +48.5% year over year. Analysts on Wall Street project that GE HealthCare Technologies (GEHC) will announce quarterly earnings of $0.91 per share in its forthcoming report, representing an increase of 1.1% year ove ...

导读： 英国品牌评估机构"品牌金融"(Brand Finance)最新发布了2025全球医疗设备品牌价值榜(Medical Devices Brands 2025)。美 敦力、费森尤斯、雅培名列前三位。 特别提示 微信机制调整，点击顶部"仪器信息网" → 右上方"…" → 设为 ★ 星标，否则很可能无法看到我们的推送。 | #1 | Medtronic | $7.4 bn | +2% | | --- | --- | --- | --- | | #2 | Fresenius | $7.3 bn | -5% | | #3 | Abbott | $5.8 bn | +6% | | #4 | Philips | $5.5 bn | +24% | | #5 | Stryker | $5.2 bn | +22% | | #6 | Siemens Healthineers | $5.2 bn | +17% | | #7 | BD | $3.3 bn | -5% | | #8 | Boston Scientific | $3.2 bn | +12% | | #d | GE HealthCare | $3.1 bn | | 榜 ...

Core Viewpoint - GE HealthCare Technologies, Inc. (GEHC) is positioned for growth due to its focus on innovations, strong fourth-quarter 2024 performance, and acquisitions, despite facing geopolitical tensions and competition [1] Company Overview - GEHC has a market capitalization of $29.71 billion and projects a 6.2% growth over the next five years, maintaining strong performance with a trailing four-quarter average earnings surprise of 6.17% [2] Factors Favoring Growth - Innovations Supporting Growth: GEHC's commitment to innovation has led to significant improvements, including the launch of Invenia Automated Breast Ultrasound Premium, which utilizes advanced AI for enhanced screening [3] - Recent launches include the AltiX AI.i edition for cardiac procedures, expected to improve efficiency and precision in care [4] - The Genesis portfolio, a cloud-based imaging software solution, aims to modernize healthcare data management and reduce operational costs [5] - The Freelium platform, unveiled at ECR 2025, promotes sustainability in MR imaging by using less than 1% of helium compared to traditional systems [6] - The company received FDA 510(k) clearance for updated Voluson Expert Series ultrasound systems, enhancing women's healthcare with superior image quality and ergonomic design [8] Acquisitions & Partnerships - GEHC is focused on partnerships and acquisitions to attract long-term customers and drive growth, including an expanded collaboration with NVIDIA to develop AI-driven healthcare solutions [9][10] - Strategic collaborations with the University of California, San Francisco, and Sutter Health aim to improve access to advanced imaging and streamline care coordination [11] Financial Performance - GEHC reported strong fourth-quarter 2024 results, with total company orders increasing 6% organically year over year, driven by strength in the U.S. market across all segments [12] - The net income margin improved to 13.5%, up 580 basis points from the prior year, due to productivity and pricing benefits [12] Challenges - GEHC faces potential challenges from new U.S. tariffs on Chinese imports, which may impact its cost structure and profitability, with an expected 10-basis-point hit to the adjusted EBIT margin [13] Estimate Trends - The Zacks Consensus Estimate for GEHC's earnings for fiscal 2025 remains stable at $4.70 per share, with first-quarter fiscal 2025 revenues estimated at $4.66 billion, indicating a 0.2% improvement year over year [14]

报名：首届全球骨科大会 | 议程更新 报名：首届全球心血管大会 | 重磅亮点 合作伙伴征集：2025全球手术机器人大会 2025年4月，据medical design and outsourcing网站报道，捷迈邦美Zimmer Biomet披露了其首席执行官、其他高管以及普通员工的薪酬变动，预计均有 所上涨。与此同时，GE医疗公布其高管以及普通员工的薪酬均有所下降。 2024年Zimmer Biomet 薪酬最高的高管是总裁兼首席执行官 Ivan Tornos，年薪为 1500万美元 ，其中包括120万美元的薪水、1180万美元的股票奖励和170万美 元的奖金。Ivan Tornos还获得了价值26万美元各类补贴，总薪酬比前一年的1020万美元 上 涨47%。 Suketu Upadhyay：首席财务官兼财务、运营以及供应链执行副总裁 # 捷迈邦美高管 薪酬 排名 Ivan Tornos：总裁兼首席执行官 年薪为 5 90万美元 ，其中包括87.6万美元的薪水、400万美元的股票奖励和82.09万美元的奖金等，此外获得价值18万美元左右的各类补贴，总薪酬较上 一年的1040万美元 下降43%。 Wilfre ...

报名：首届全球骨科大会 | 议程更新 报名：首届全球心血管大会 | 重磅亮点 合作伙伴征集：2025全球手术机器人大会 2025年4月，据medical design and outsourcing网站报道，捷迈邦美Zimmer Biomet披露了其首席执行官、其他高管以及普通员工的薪酬变动，预计均有 所上涨。与此同时，GE医疗公布其高管以及普通员工的薪酬均有所下降。 2024年Zimmer Biomet 薪酬最高的高管是总裁兼首席执行官 Ivan Tornos，年薪为 1500万美元 ，其中包括120万美元的薪水、1180万美元的股票奖励和170万美 元的奖金。Ivan Tornos还获得了价值26万美元各类补贴，总薪酬比前一年的1020万美元 上 涨47%。 Suketu Upadhyay：首席财务官兼财务、运营以及供应链执行副总裁 # 捷迈邦美高管 薪酬 排名 Ivan Tornos：总裁兼首席执行官 年薪为 5 90万美元 ，其中包括87.6万美元的薪水、400万美元的股票奖励和82.09万美元的奖金等，此外获得价值18万美元左右的各类补贴，总薪酬较上 一年的1040万美元 下降43%。 Wilfre ...

GE HealthCare Technologies (GEHC) shares soared 10.6% in the last trading session to close at $64.98. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 31.4% loss over the past four weeks.The upside can be attributed to relief-rally across global markets following the announcement of a 90-day pause on tariff hike by the United States.This medical technology company is expected to post quarterly earnings of $0.91 per share in its up ...

If you like to see more ideas, please subscribe to the premium service "Value in Corporate Events" here and try the free trial. In this service we cover major earnings events, M&A, IPOs and other significant corporate events with actionable ideas. Furthermore, we provide coverage of situations and names on request!Shares of GE HealthCare (NASDAQ: GEHC ) have been a publicly traded entity since early 2023, when the healthcare business was spun off from GE. A $60 stock at the time, has largely traded in a $60 ...

报名：首届全球眼科大会 | 议程更新 报名：首届全球骨科大会 | 议程更新 报名：首届全球心血管大会 | 奖项申报 合作伙伴征集：2025全球手术机器人大会 过去一周，多家知名医疗科技公司的股票表现不佳，公司 正在努力应对特朗普政府发起的新一轮全球贸易 战。 标准普尔500指数（S&P 500）昨日短暂进入熊市，随着关于政府和其他国家可能采取的关税措施的 混乱消息，该指数大幅波动。 总体而言，标准普尔500指数在过去一个月下跌了 12% ，在过去五天内下跌了 9% 。 医疗科技股在3月就因特朗普的关税政策而下跌。特朗普上周对几乎所有国家的进口商品实施新的税收， 引发了此轮暴跌。以下是过去一个月（百分比为四舍五入）10大医疗科技公司的股票表现： | | 10大医疗科技公司股票表现 | | | --- | --- | --- | | 序号 | Company | Stock Performance (1 Month) | | 1 | Medtronic (NYSE: MDT) | -12% | | 2 | Johnson & Johnson (NYSE: JNJ) | -10% | | 3 | Stryker ( ...

Shares in GE HealthCare Technologies (GEHC -10.04%) were down 9.5% at 1 p.m. today. The decline follows the U.S.'s wide-scale implementation of tariffs. GE HealthCare is a truly global company, and the tariff actions will negatively impact its business.GE HealthCare and tariffsThe company generated about $9 billion in revenue from North America in 2024, and $10.7 billion from the rest of the world (including $2.4 billion from China). It's a global company, competing with leading healthcare equipment compani ...